Dyadic International

DYAI

Market cap $35M

Overview Fund Activity

0.9669 USD

-0.0228

2.3%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.9500

-0.0169

1.75%

1 day

-2.3%

5 days

6.25%

1 month

13.75%

3 months

2.4%

6 months

-31.43%

Year to date

-44.43%

1 year

-22.02%

5 years

-87.54%

10 years

-71.56%

About: Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Employees: 6

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

9% more funds holding

Funds holding: 34 [Q1] → 37 (+3) [Q2]

0.32% less ownership

Funds ownership: 16.81% [Q1] → 16.49% (-0.32%) [Q2]

28% less capital invested

Capital invested by funds: $6.83M [Q1] → $4.91M (-$1.92M) [Q2]

See Fund Rankings

Financial journalist opinion

Dyadic to Present at Investor Conferences and BPI East

JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that Joe Hazelton, Dyadic's President & Chief Operating Officer, will attend and present at the following conferences: H.C.

Dyadic to Present at Investor Conferences and BPI East

Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript

Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Joseph P. Hazelton - President & COO Mark A.

Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

JUPITER, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced its financial results for the second quarter of 2025, highlighting recent company progress.

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025.

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share. The Company expects the gross proceeds from this offering to be approximately $5.75 million, before deducting the underwriting discount and other offering expenses. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions.

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions.

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it has commenced an underwritten public offering of shares of common stock.

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

JUPITER, Fla.--(BUSINESS WIRE)---- $DYAI #BioSolutions--Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions to reflect focus on commercializing non-therapeutic proteins.

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets.

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025.

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

See News Rankings

Charts implemented using Lightweight Charts™